Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy

Hagemann A, May T, Nieder E, Witte-Boelt K, Pohlmann-Eden B, Elger CE, Tergau F, Schulze-Bonhage A, Straub H-B, Arnold S, Brandt C (2013)
Epilepsy Research 104(1-2): 140-150.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor/in
; ; ; ; ; ; ; ; ; ;
Abstract / Bemerkung
The aim of this study was to investigate the change of health related quality of life (HRQoL), anxiety and depression in adult patients in whom an adjunctive treatment with levetiracetam (LEV) was converted to a LEV monotherapy. A prospective, open, investigator initiated multicenter study enrolled 140 patients in whom LEV was added to the existing antiepileptic medication. A total of 65 patients who benefited from the 16-week add-on treatment with LEV (>= 50% seizure reduction) were converted to LEV monotherapy (16-week follow-up). In LEV responders, HRQoL, anxiety and depression improved after add-on of LEV. The subsequent conversion to LEV monotherapy did not lead to a significant change in HRQoL, anxiety and depression. However, comparing baseline with LEV monotherapy, the improvements remained significant for most dimensions of HRQoL and for anxiety and depression. Patients' ratings of efficacy of LEV were related with their HRQoL after the conversion to monotherapy. Add-on therapy of LEV improved HRQoL, anxiety and depression in LEV responders. Conversion to a LEV monotherapy did not inevitably improve HRQoL in LEV responders, but the positive effect was maintained in the majority of the patients. The effects were highly related to seizure reduction. (c) 2012 Elsevier B.V. All rights reserved.
Erscheinungsjahr
Zeitschriftentitel
Epilepsy Research
Band
104
Ausgabe
1-2
Seite(n)
140-150
ISSN
PUB-ID

Zitieren

Hagemann A, May T, Nieder E, et al. Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. Epilepsy Research. 2013;104(1-2):140-150.
Hagemann, A., May, T., Nieder, E., Witte-Boelt, K., Pohlmann-Eden, B., Elger, C. E., Tergau, F., et al. (2013). Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. Epilepsy Research, 104(1-2), 140-150. doi:10.1016/j.eplepsyres.2012.08.005
Hagemann, A., May, T., Nieder, E., Witte-Boelt, K., Pohlmann-Eden, B., Elger, C. E., Tergau, F., Schulze-Bonhage, A., Straub, H. - B., Arnold, S., et al. (2013). Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. Epilepsy Research 104, 140-150.
Hagemann, A., et al., 2013. Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. Epilepsy Research, 104(1-2), p 140-150.
A. Hagemann, et al., “Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy”, Epilepsy Research, vol. 104, 2013, pp. 140-150.
Hagemann, A., May, T., Nieder, E., Witte-Boelt, K., Pohlmann-Eden, B., Elger, C.E., Tergau, F., Schulze-Bonhage, A., Straub, H.-B., Arnold, S., Brandt, C.: Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. Epilepsy Research. 104, 140-150 (2013).
Hagemann, Anne, May, Theodor, Nieder, Esther, Witte-Boelt, Karin, Pohlmann-Eden, Bernd, Elger, Christian E., Tergau, Frithjof, Schulze-Bonhage, Andreas, Straub, Hans-Beatus, Arnold, Stephan, and Brandt, Christian. “Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy”. Epilepsy Research 104.1-2 (2013): 140-150.

4 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

The influence of levetiracetam in cognitive performance in healthy individuals: neuropsychological, behavioral and electrophysiological approach.
Magalhães JC, Gongora M, Vicente R, Bittencourt J, Tanaka G, Velasques B, Teixeira S, Morato G, Basile LF, Arias-Carrión O, Pompeu FA, Cagy M, Ribeiro P., Clin Psychopharmacol Neurosci 13(1), 2015
PMID: 25912541
Risk factors for postoperative depression: A retrospective analysis of 248 subjects operated on for drug-resistant epilepsy.
Barbieri V, Cardinale F, Gozzo F, Pelliccia V, Nobili L, Casaceli G, Fuschillo D, Castana L, Cossu M, Lo Russo G, Tassi L, Gambini O., Epilepsia 56(10), 2015
PMID: 26299461

37 References

Daten bereitgestellt von Europe PubMed Central.

The validity of the Hospital Anxiety and Depression Scale. An updated literature review.
Bjelland I, Dahl AA, Haug TT, Neckelmann D., J Psychosom Res 52(2), 2002
PMID: 11832252
Therapeutic strategies to avoid long-term adverse outcomes of neonatal antiepileptic drug exposure.
Forcelli PA, Janssen MJ, Stamps LA, Sweeney C, Vicini S, Gale K., Epilepsia 51 Suppl 3(), 2010
PMID: 20618394
Prevalence of anxiety disorders in patients with refractory focal epilepsy--a prospective clinic based survey.
Brandt C, Schoendienst M, Trentowska M, May TW, Pohlmann-Eden B, Tuschen-Caffier B, Schrecke M, Fueratsch N, Witte-Boelt K, Ebner A., Epilepsy Behav 17(2), 2010
PMID: 20075009
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ; Levetiracetam Monotherapy Study Group., Neurology 68(6), 2007
PMID: 17283312
Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial.
Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I., Neurology 55(2), 2000
PMID: 10908898

Cohen, 1988
Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group.
Cramer JA, Arrigo C, Van Hammee G, Gauer LJ, Cereghino JJ., Epilepsia 41(7), 2000
PMID: 10897159
Differentiating anxiety and depression symptoms in patients with partial epilepsy.
Cramer JA, Brandenburg N, Xu X., Epilepsy Behav 6(4), 2005
PMID: 15907750
Quality of life improvement with conversion to lamotrigine monotherapy.
Cramer JA, Hammer AE, Kustra RP., Epilepsy Behav 5(2), 2004
PMID: 15123024
Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory.
Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B., Epilepsia 39(1), 1998
PMID: 9578017
Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam.
Cramer JA, Van Hammee G; N132 Study Group., Epilepsy Behav 4(2), 2003
PMID: 12697135
Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study.
Deckers CL, Hekster YA, Keyser A, van Lier HJ, Meinardi H, Renier WO., Epilepsia 42(11), 2001
PMID: 11879339
Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug.
De Smedt T, Raedt R, Vonck K, Boon P., CNS Drug Rev 13(1), 2007
PMID: 17461890
An active-control trial of lamotrigine monotherapy for partial seizures.
Gilliam F, Vazquez B, Sackellares JC, Chang GY, Messenheimer J, Nyberg J, Risner ME, Rudd GD., Neurology 51(4), 1998
PMID: 9781523
Monotherapy or polytherapy for epilepsy?
Guberman A., Can J Neurol Sci 25(4), 1998
PMID: 9827238
Depression and anxiety in epilepsy patients.
Harden CL., Epilepsy Behav 3(3), 2002
PMID: 12662616

Herrmann, 1995
Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study.
Lopez-Gongora M, Martinez-Domeno A, Garcia C, Escartin A., Epileptic Disord 10(4), 2008
PMID: 19017572
Effect of levetiracetam on depression and anxiety in adult epileptic patients.
Mazza M, Martini A, Scoppetta M, Mazza S., Prog. Neuropsychopharmacol. Biol. Psychiatry 32(2), 2007
PMID: 18031881
Psychometric Properties of the German Translation of the QOLIE-31.
May TW, Pfafflin M, Cramer JA., Epilepsy Behav 2(2), 2001
PMID: 12609192
The presence and clinical implications of depression in a community population of adults with epilepsy.
Mensah SA, Beavis JM, Thapar AK, Kerr M., Epilepsy Behav 8(1), 2005
PMID: 16337435
A community study of the presence of anxiety disorder in people with epilepsy.
Mensah SA, Beavis JM, Thapar AK, Kerr MP., Epilepsy Behav 11(1), 2007
PMID: 17532266
The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study.
Morrell MJ, Leppik I, French J, Ferrendelli J, Han J, Magnus L., Epilepsy Res. 54(2-3), 2003
PMID: 12837566
Suicidal ideation in epilepsy and levetiracetam therapy.
Mula M, Sander JW., Epilepsy Behav 11(1), 2007
PMID: 17544331
Psychiatric adverse events during levetiracetam therapy.
Mula M, Trimble MR, Yuen A, Liu RS, Sander JW., Neurology 61(5), 2003
PMID: 12963770
Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures.
Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J; N166 Levetiracetam Study Group., Neurology 70(8), 2008
PMID: 18285535
A psychosocial view of anxiety and depression in epilepsy.
de Souza EA, Salgado PC., Epilepsy Behav 8(1), 2005
PMID: 16356782
The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ, Somerville ER, Van Paesschen W, Ryvlin P, Schelstraete I., Epilepsy Res. 76(1), 2007
PMID: 17681453
Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy.
Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ., Epilepsy Behav 10(1), 2006
PMID: 17079191
Discontinuation of levetiracetam because of behavioral side effects: a case-control study.
White JR, Walczak TS, Leppik IE, Rarick J, Tran T, Beniak TE, Matchinsky DJ, Gumnit RJ., Neurology 61(9), 2003
PMID: 14610123
Clinically important change in quality of life in epilepsy.
Wiebe S, Matijevic S, Eliasziw M, Derry PA., J. Neurol. Neurosurg. Psychiatry 73(2), 2002
PMID: 12122166

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 22959715
PubMed | Europe PMC

Suchen in

Google Scholar